Literature DB >> 12234876

Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Masaya Takei, Hideyuki Fukuda, Ryuta Kishii, Youko Kadowaki, Yukiko Atobe, Masaki Hosaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234876      PMCID： PMC128794          DOI： 10.1128/AAC.46.10.3337-3338.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  19 in total

1.  In vitro activity of gatifloxacin against Streptococcus pneumoniae isolates in Germany.

Authors:  R R Reinert; A Al-Lahham; S Lemmen; R Lütticken
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

2.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).

Authors:  B A Odland; R N Jones; J Verhoef; A Fluit; M L Beach
Journal:  Diagn Microbiol Infect Dis       Date:  1999-08       Impact factor: 2.803

5.  Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

8.  Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

Authors:  G Sindelar; X Zhao; A Liew; Y Dong; T Lu; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light.

Authors:  K Marutani; M Matsumoto; Y Otabe; M Nagamuta; K Tanaka; A Miyoshi; T Hasegawa; H Nagano; S Matsubara; R Kamide
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191
View more
  1 in total

1.  In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.

Authors:  G Hansen; S Swanzy; R Gupta; B Cookson; A P Limaye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.